Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Brigham and Women's Hospital
Study ID
NCT06483659
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Postoperative Pain

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Oxytocin — DRUG
    Intravenous Oxytocin infusion
  • Placebo — DRUG
    0.9% Saline

Study Details

This is a randomized, double-blinded, placebo-controlled trial to compare the effectiveness of IV oxytocin infusion to placebo on peri-operative opioid consumption and reducing post-operative pain following a minimally invasive hysterectomy under general anesthesia.

Key Dates

Start date
Jun 1, 2025
Status verified
Dec 2025
Primary completion
Jul 1, 2026
Completion
Dec 1, 2026

Study Design

Enrollment
152 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Medication
    one group will receive Oxytocin infusion: 30 IU in 500 ml of 0.9% normal saline .
  • Placebo Comparator: Placebo
    one group will receive 500 ml of 0.9% normal saline

Primary Outcome Measure

Post-operative pain [ Time Frame: Between 2-4 hours after surgery completion (in the PACU) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Brigham and Women's HospitalBostonMassachusetts02215-

Find similar trials in Boston, MA

By research site
Brigham and Women's Hospital· Boston, MA

Related Studies